Total pharma industry venture financing deals in Q2 2019 worth $3.72bn were announced globally, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

The value marked a decrease of 24.9% over the previous quarter and a drop of 29.5% when compared with the last four-quarter average, which stood at $5.34bn.

Comparing deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $2.8bn. At the country level, the US topped the list in terms of deal value at $2.72bn.

In terms of volumes, North America emerged as the top region for pharma industry venture financing deals globally, followed by Europe and then Asia-Pacific.

The top country in terms of venture financing deals activity in Q2 2019 was the US with 158 deals, followed by China with 16 and the UK with ten.

In 2019, as of the end of Q2 2019, pharma venture financing deals worth $8.7bn were announced globally, marking a decrease of 29.5% year on year.

Pharma industry venture financing deals in Q2 2019: Top deals

The top five pharma industry venture financing deals accounted for 17.8% of the overall value during Q2 2019.

The combined value of the top five pharma industry venture financing deals stood at $661.83m, against the overall value of $3.72bn recorded for the quarter.

The top five pharma industry venture financing deals tracked by GlobalData in Q2 2019 were:

1) Deyi Capital, Gaoke Xinyi Capital, Gongqingcheng Hanren, Huaxin Century Investment Group, Loyal Valley Capital, Nanjing Gaoke Xinchuang Investment, Qianlong Capital, SDIC Unity Capital, Shiyu Capital Group and Yuansheng Venture Capital’s $170.83m venture financing of Allist Shanghai Pharmaceutical Technology

2) The $142m venture financing of Poseida Therapeutics by Aisling Capital, Boxer Capital, Longitude Capital Management Co, Malin Corporation, Novartis Pharma, Pentwater Capital Management, Perceptive Advisors and Vivo Capital

3) ArrowMark Partners, Bain Capital, Boxer Capital, BVF Partners, GlaxoSmithKline, HBM Healthcare Investments, LifeArc, Orbimed Advisors, Perceptive Advisors, Pfizer Venture Investments, Samsara BioCapital and Surveyor Capital’s $125m venture financing of SpringWorks Therapeutics

4) The $120m venture financing of AlloVir by EcoR1 Capital, F2 Ventures, Fidelity Management & Research, Gilead Sciences, SVB Leerink, Redmile Group, Samsara BioCapital and Invus Group

5) Alexandria Venture Investments, Altitude Life Science Ventures, ARCH Venture Partners, Boxer Capital, Illumina Ventures, Matrix Capital Management Company, Menlo Ventures, RTW Investments and Venrock’s venture financing of Encoded Genomics for $104m.

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.